Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Holdings Trimmed by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 29.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,507,296 shares of the biotechnology company's stock after selling 1,067,277 shares during the period. T. Rowe Price Investment Management Inc. owned 2.00% of Arrowhead Pharmaceuticals worth $47,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in shares of Arrowhead Pharmaceuticals by 9.4% during the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company's stock valued at $373,000 after acquiring an additional 1,658 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Arrowhead Pharmaceuticals by 11.6% in the fourth quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company's stock worth $525,000 after purchasing an additional 2,907 shares during the period. Empowered Funds LLC acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $268,000. Nordea Investment Management AB raised its position in shares of Arrowhead Pharmaceuticals by 6.3% during the fourth quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company's stock valued at $2,463,000 after buying an additional 7,776 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $434,000. Institutional investors own 62.61% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ARWR shares. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. B. Riley reaffirmed a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Stock Up 4.1 %

NASDAQ:ARWR traded up $0.57 during mid-day trading on Friday, hitting $14.61. 687,536 shares of the company's stock were exchanged, compared to its average volume of 1,446,242. The business has a fifty day moving average price of $14.06 and a 200 day moving average price of $18.27. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The company has a market cap of $2.01 billion, a PE ratio of -2.82 and a beta of 0.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. This trade represents a 1.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 275,880 shares of company stock valued at $4,034,037. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.